Gene therapy injection aims to halt blinding eye disease
Disease control
Not yet recruiting
This trial tests a gene therapy called PST-611 in people aged 65 and older with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. PST-611 is a DNA plasmid injected into the eye muscle that instructs cells to produce human transferri…
Phase: PHASE2 • Sponsor: Eyevensys • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC